In addition, a positive correlation between the expression of programmed death ligand-1 (PD-L1) and the presence of mutated BRAFV600E has been shown in BRAF-mt tumours, with higher levels of CD8+ tumour-infiltrating lymphocytes observed in BRAF-mt colorectal tumours,67 suggesting that BRAF-mt mCRC patients might benefit from immunotherapy. Here, CD8A is linked to neoplasm.